{"pmid":32424293,"title":"COVID-19 in persons with chronic myeloid leukaemia.","text":["COVID-19 in persons with chronic myeloid leukaemia.","We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation.","Leukemia","Li, Weiming","Wang, Danyu","Guo, Jingming","Yuan, Guolin","Yang, Zhuangzhi","Gale, Robert Peter","You, Yong","Chen, Zhichao","Chen, Shiming","Wan, Chucheng","Zhu, Xiaojian","Chang, Wei","Sheng, Lingshuang","Cheng, Hui","Zhang, Youshan","Li, Qing","Qin, Jun","Meng, Li","Jiang, Qian","32424293"],"abstract":["We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation."],"journal":"Leukemia","authors":["Li, Weiming","Wang, Danyu","Guo, Jingming","Yuan, Guolin","Yang, Zhuangzhi","Gale, Robert Peter","You, Yong","Chen, Zhichao","Chen, Shiming","Wan, Chucheng","Zhu, Xiaojian","Chang, Wei","Sheng, Lingshuang","Cheng, Hui","Zhang, Youshan","Li, Qing","Qin, Jun","Meng, Li","Jiang, Qian"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424293","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41375-020-0853-6","locations":["Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Imatinib Mesylate"],"topics":["Prevention"],"weight":1,"_version_":1667352728691539968,"score":9.490897,"similar":[{"pmid":32332856,"pmcid":"PMC7180672","title":"COVID-19 in persons with haematological cancers.","text":["COVID-19 in persons with haematological cancers.","Infection with SARS-CoV-2, the cause of coronavirus infectious disease-19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing. Several studies report outcomes of COVID-19 in predominately well persons. There are also some data on COVID-19 in persons with predominately solid cancer but controversy whether these persons have the same outcomes. We conducted a cohort study at two centres in Wuhan, China, of 128 hospitalised subjects with haematological cancers, 13 (10%) of whom developed COVID-19. We also studied 226 health care providers, 16 of whom developed COVID-19 and 11 of whom were hospitalised. Co-variates were compared with the 115 subjects with haematological cancers without COVID-19 and with 11 hospitalised health care providers with COVID-19. There were no significant differences in baseline co-variates between subjects with haematological cancers developing or not developing COVID-19. Case rates for COVID-19 in hospitalised subjects with haematological cancers was 10% (95% Confidence Interval [CI], 6, 17%) compared with 7% (4, 12%; P = 0.322) in health care providers. However, the 13 subjects with haematological cancers had more severe COVID-19 and more deaths compared with hospitalised health care providers with COVID-19. Case fatality rates were 62% (32, 85%) and 0 (0, 32%; P = 0.002). Hospitalised persons with haematological cancers have a similar case rate of COVID-19 compared with normal health care providers but have more severe disease and a higher case fatality rate. Because we were unable to identify specific risk factors for COVID-19 in hospitalised persons with haematological cancers, we suggest increased surveillance and possible protective isolation.","Leukemia","He, Wenjuan","Chen, Lei","Chen, Li","Yuan, Guolin","Fang, Yun","Chen, Wenlan","Wu, Di","Liang, Bo","Lu, Xiaoting","Ma, Yanling","Li, Lei","Wang, Hongxiang","Chen, Zhichao","Li, Qiubai","Gale, Robert Peter","32332856"],"abstract":["Infection with SARS-CoV-2, the cause of coronavirus infectious disease-19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing. Several studies report outcomes of COVID-19 in predominately well persons. There are also some data on COVID-19 in persons with predominately solid cancer but controversy whether these persons have the same outcomes. We conducted a cohort study at two centres in Wuhan, China, of 128 hospitalised subjects with haematological cancers, 13 (10%) of whom developed COVID-19. We also studied 226 health care providers, 16 of whom developed COVID-19 and 11 of whom were hospitalised. Co-variates were compared with the 115 subjects with haematological cancers without COVID-19 and with 11 hospitalised health care providers with COVID-19. There were no significant differences in baseline co-variates between subjects with haematological cancers developing or not developing COVID-19. Case rates for COVID-19 in hospitalised subjects with haematological cancers was 10% (95% Confidence Interval [CI], 6, 17%) compared with 7% (4, 12%; P = 0.322) in health care providers. However, the 13 subjects with haematological cancers had more severe COVID-19 and more deaths compared with hospitalised health care providers with COVID-19. Case fatality rates were 62% (32, 85%) and 0 (0, 32%; P = 0.002). Hospitalised persons with haematological cancers have a similar case rate of COVID-19 compared with normal health care providers but have more severe disease and a higher case fatality rate. Because we were unable to identify specific risk factors for COVID-19 in hospitalised persons with haematological cancers, we suggest increased surveillance and possible protective isolation."],"journal":"Leukemia","authors":["He, Wenjuan","Chen, Lei","Chen, Li","Yuan, Guolin","Fang, Yun","Chen, Wenlan","Wu, Di","Liang, Bo","Lu, Xiaoting","Ma, Yanling","Li, Lei","Wang, Hongxiang","Chen, Zhichao","Li, Qiubai","Gale, Robert Peter"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32332856","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1038/s41375-020-0836-7","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666138493963730944,"score":397.1831},{"pmid":32415723,"title":"Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.","text":["Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic.","The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources.","Intern Med J","Di Ciaccio, Pietro","McCaughan, Georgia","Trotman, Judith","Ho, Phoebe Joy","Cheah, Chan Y","Gangatharan, Shane","Wight, Joel","Ku, Matthew","Quach, Hang","Gasiorowski, Robin","Polizzotto, Mark N","Prince, Henry Miles","Mulligan, Stephen","Tam, Constantine S","Gregory, Gareth","Hapgood, Greg","Spencer, Andrew","Dickinson, Michael","Latimer, Maya","Johnston, Anna","Armytage, Tasman","Lee, Cindy","Cochrane, Tara","Berkhahn, Leanne","Weinkove, Robert","Doocey, Richard","Harrison, Simon J","Webber, Nicholas","Lee, Hui-Peng","Chapman, Scott","Campbell, Belinda A","Gibbs, Simon D J","Hamad, Nada","32415723"],"abstract":["The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources."],"journal":"Intern Med J","authors":["Di Ciaccio, Pietro","McCaughan, Georgia","Trotman, Judith","Ho, Phoebe Joy","Cheah, Chan Y","Gangatharan, Shane","Wight, Joel","Ku, Matthew","Quach, Hang","Gasiorowski, Robin","Polizzotto, Mark N","Prince, Henry Miles","Mulligan, Stephen","Tam, Constantine S","Gregory, Gareth","Hapgood, Greg","Spencer, Andrew","Dickinson, Michael","Latimer, Maya","Johnston, Anna","Armytage, Tasman","Lee, Cindy","Cochrane, Tara","Berkhahn, Leanne","Weinkove, Robert","Doocey, Richard","Harrison, Simon J","Webber, Nicholas","Lee, Hui-Peng","Chapman, Scott","Campbell, Belinda A","Gibbs, Simon D J","Hamad, Nada"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32415723","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/imj.14859","keywords":["covid-19","chronic lymphocytic leukaemia","lymphoma","myeloma"],"locations":["Australia","New Zealand","Australian","New Zealand","lymphoma"],"countries":["Australia","New Zealand"],"countries_codes":["AUS|Australia","NZL|New Zealand"],"topics":["Prevention"],"weight":1,"_version_":1666991242696720384,"score":228.08556},{"pmid":32368790,"title":"Ph+ Acute Lymphoblastic Leukaemia in Italy During the Covid-19 Pandemic. A Campus ALL Study.","text":["Ph+ Acute Lymphoblastic Leukaemia in Italy During the Covid-19 Pandemic. A Campus ALL Study.","The recent spread of the Covid-19 infection has raised important questions within the haematology community on how best to manage and treat patients with haematological malignancies, particularly acute leukaemias. Italy has witnessed a dramatic raise in infections and death rates, that has hit in particular certain areas of the most populated Northern regions of the country (Lombardia, Veneto, Piemonte, Emilia Romagna). Within the nationwide Campus ALL programme in the last week of March we sent a questionnaire addressing different issues related to the management of adult ALL patients during the Covid-19 pandemic to 40 haematology centres located on the entire territory.","Br J Haematol","Foa, Robin","Bonifacio, Massimiliano","Chiaretti, Sabina","Curti, Antonio","Candoni, Anna","Fava, Carmen","Ciccone, Maria","Pizzolo, Giovanni","Ferrara, Felicetto","32368790"],"abstract":["The recent spread of the Covid-19 infection has raised important questions within the haematology community on how best to manage and treat patients with haematological malignancies, particularly acute leukaemias. Italy has witnessed a dramatic raise in infections and death rates, that has hit in particular certain areas of the most populated Northern regions of the country (Lombardia, Veneto, Piemonte, Emilia Romagna). Within the nationwide Campus ALL programme in the last week of March we sent a questionnaire addressing different issues related to the management of adult ALL patients during the Covid-19 pandemic to 40 haematology centres located on the entire territory."],"journal":"Br J Haematol","authors":["Foa, Robin","Bonifacio, Massimiliano","Chiaretti, Sabina","Curti, Antonio","Candoni, Anna","Fava, Carmen","Ciccone, Maria","Pizzolo, Giovanni","Ferrara, Felicetto"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32368790","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16758","locations":["Italy","Northern","Lombardia","Veneto","Piemonte","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138496223412225,"score":192.86615},{"pmid":32379921,"title":"Survival study of hospitalized patients with concurrent Covid-19 and haematological malignancies.","text":["Survival study of hospitalized patients with concurrent Covid-19 and haematological malignancies.","The prevalence of cancer in patients with the novel coronavirus disease 2019 (Covid-19), caused by the SARS-CoV-2 infection, is uncertain. In a pooled meta-analysis including 11 retrospective studies, the prevalence of cancer was 2% (Desai et al, 2020). Patients with cancer and Covid-19 have been described to have a higher risk of suffering severe events (intensive care unit admission and invasive ventilation or dying) in a retrospective study including 18 patients with cancer (Liang et al, 2020). One study reported 13 Covid-19 cases in a cohort of 128 hospitalized patients with haematological cancers, with no significant differences in baseline co-variates between patients developing or not developing Covid-19 (He et al, 2020).","Br J Haematol","Martin-Moro, Fernando","Marquet, Juan","Piris, Miguel","Michael, Berta M","Saez, Adolfo J","Corona, Magdalena","Jimenez, Carlos","Astibia, Beatriz","Garcia, Irene","Rodriguez, Eulalia","Garcia-Hoz, Carlota","Fortun-Abete, Jesus","Herrera, Pilar","Lopez-Jimenez, Javier","32379921"],"abstract":["The prevalence of cancer in patients with the novel coronavirus disease 2019 (Covid-19), caused by the SARS-CoV-2 infection, is uncertain. In a pooled meta-analysis including 11 retrospective studies, the prevalence of cancer was 2% (Desai et al, 2020). Patients with cancer and Covid-19 have been described to have a higher risk of suffering severe events (intensive care unit admission and invasive ventilation or dying) in a retrospective study including 18 patients with cancer (Liang et al, 2020). One study reported 13 Covid-19 cases in a cohort of 128 hospitalized patients with haematological cancers, with no significant differences in baseline co-variates between patients developing or not developing Covid-19 (He et al, 2020)."],"journal":"Br J Haematol","authors":["Martin-Moro, Fernando","Marquet, Juan","Piris, Miguel","Michael, Berta M","Saez, Adolfo J","Corona, Magdalena","Jimenez, Carlos","Astibia, Beatriz","Garcia, Irene","Rodriguez, Eulalia","Garcia-Hoz, Carlota","Fortun-Abete, Jesus","Herrera, Pilar","Lopez-Jimenez, Javier"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32379921","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bjh.16801","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666597097332277248,"score":177.37466},{"pmid":32413201,"title":"Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.","text":["Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.","BACKGROUND: Worldwide, the number of SARS-CoV-2 infections is increasing. Serological immunoglobulin tests may help to better understand the development of immune mechanisms against SARS-CoV-2 in COVID-19 cases and exposed but asymptomatic individuals. The aim of this study was to investigate exposure to SARS-CoV-2, symptoms and antibody responses in a large sample of health care workers following a COVID-19 outbreak. METHODS: A COVID-19 outbreak among staff members of a major German children's and women's hospital was followed by massive RT-PCR SARS-CoV-2 tests and provided the opportunity to study symptoms, chains of infection and SARS-CoV-2 specific antibody responses (IgG and IgA) by ELISA. Study participants were classified as COVID-19 cases, and persons with close, moderate or no exposure to SARS-CoV-2 in the clinical setting, respectively. RESULTS: Out of 201 study participants, 31 were COVID-19 cases. While most study participants experienced many symptoms indicative for SARS-CoV-2 infection, anosmia and coughing were remarkably more frequent in COVID-19 cases. Approximately 80% of COVID-19 cases developed some specific antibody response (IgA and IgG) approximately 3 weeks after onset of symptoms. Subjects in the non COVID-19 groups had also elevated IgG (1.8%) and IgA values (7.6%) irrespective of contact history with cases. CONCLUSION: We found that a significant number of diseased did not develop relevant antibody responses three weeks after symptom onset. Our data also suggests that exposure to COVID-19 positive co-workers in a hospital setting is not leading to the development of measurable immune responses in a significant proportion of asymptomatic contact-persons.","Pediatr Allergy Immunol","Brandstetter, Susanne","Roth, Samra","Harner, Susanne","Buntrock-Dopke, Heike","Toncheva, Antoaneta","Borchers, Natascha","Gruber, Rudolf","Ambrosch, Andreas","Kabesch, Michael","32413201"],"abstract":["BACKGROUND: Worldwide, the number of SARS-CoV-2 infections is increasing. Serological immunoglobulin tests may help to better understand the development of immune mechanisms against SARS-CoV-2 in COVID-19 cases and exposed but asymptomatic individuals. The aim of this study was to investigate exposure to SARS-CoV-2, symptoms and antibody responses in a large sample of health care workers following a COVID-19 outbreak. METHODS: A COVID-19 outbreak among staff members of a major German children's and women's hospital was followed by massive RT-PCR SARS-CoV-2 tests and provided the opportunity to study symptoms, chains of infection and SARS-CoV-2 specific antibody responses (IgG and IgA) by ELISA. Study participants were classified as COVID-19 cases, and persons with close, moderate or no exposure to SARS-CoV-2 in the clinical setting, respectively. RESULTS: Out of 201 study participants, 31 were COVID-19 cases. While most study participants experienced many symptoms indicative for SARS-CoV-2 infection, anosmia and coughing were remarkably more frequent in COVID-19 cases. Approximately 80% of COVID-19 cases developed some specific antibody response (IgA and IgG) approximately 3 weeks after onset of symptoms. Subjects in the non COVID-19 groups had also elevated IgG (1.8%) and IgA values (7.6%) irrespective of contact history with cases. CONCLUSION: We found that a significant number of diseased did not develop relevant antibody responses three weeks after symptom onset. Our data also suggests that exposure to COVID-19 positive co-workers in a hospital setting is not leading to the development of measurable immune responses in a significant proportion of asymptomatic contact-persons."],"journal":"Pediatr Allergy Immunol","authors":["Brandstetter, Susanne","Roth, Samra","Harner, Susanne","Buntrock-Dopke, Heike","Toncheva, Antoaneta","Borchers, Natascha","Gruber, Rudolf","Ambrosch, Andreas","Kabesch, Michael"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413201","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/pai.13278","keywords":["covid-19 outbreak","covid-19 pandemic","sars-cov-2","antibody response","health care workers","immonuglobulin development","infection chain"],"locations":["German"],"countries":["Germany"],"countries_codes":["DEU|Germany"],"topics":["Diagnosis"],"weight":1,"_version_":1666989866109370368,"score":168.49884}]}